Endocrine Abstracts

Bone loss is a frequent complication of aromatase inhibitors (AIs) therapy in women with breast cancer. Bone-active drugs are effective in protecting the skeleton from detrimental actions of AIs. However, bone mineral density (BMD) was the primary end-point in most of published studies, whereas data on fractures were scant and mainly limited to denosumab. In this prospective study, we investigated the effects of denosumab, oral bisphosphonates and intravenous zoledronate on ri...

Background: Type 2 diabetes mellitus (T2D) is associated with an increased risk of fractures. Research on the effects of sodium-glucose cotransporter 2 (SGLT-2) inhibitors is scarce and unsettled. We aimed to investigate the risk of major osteoporotic fractures (MOF) – i.e., hip, vertebral, humerus, and forearm fractures – with SGLT2 inhibitors compared to glucagon-like peptide 1 (GLP-1) receptor agonists when either is used in combination with metformin.<p class...

Background: In individuals with primary hyperparathyroidism (PHPT), the utility of preoperative bisphosphonate administration in prevention of post-curative-parathyroidectomy hungry bone syndrome (HBS) and effects on long-term bone accrual are uncertain.Objectives: To estimate the effect of preoperative administration of single infusion of zoledronic acid (ZA) on occurrence of HBS and gain in bone mineral density (BMD) at one year in individuals with PHP...

Background: Zoledronic acid (ZOL) administration may cause acute phase adverse reactions (APR), which manifest with fever, malaise, bone and muscular pain, headache and/or gastrointestinal disturbances. Previous data suggest that high N-terminal propeptide of type 1 collagen (P1NP) and low 25, OH-vitaminD (VitD) levels are associated with higher incidence of APR, while the previous use of bisphosphonates is a protective factor. Lately, ZOL has been frequently used to mitigate ...

Key4OI : Development and implementation of a Standard set of Outcome measures for Osteogenesis Imperfecta. Osteogenesis Imperfecta (OI) is a genetic disorder also known as ‘brittle bone disease’. The clinical manifestation of OI shows a wide variation. Therefore, care for patients with OI requires an interdisciplinary approach. The effectiveness of particular interventions and treatment protocols of interdisciplinary teams is not clear due to a non-standardized and w...

AZP-3601, a long-acting PTH/PTHrP(1-36) analog, is a candidate new treatment option for hypoparathyroidism (HP). As compared to conventional PTH(1-34), AZP-3601 binds with higher affinity to the R0 conformation of the PTH-1 receptor, resulting in prolonged signaling and sustained elevations in blood calcium (Ca++) in vivo, despite a very short circulating half-life. We assessed whether repeated injection of AZP-3601 into TPTX rats at doses aimed to normalize serum C...